SIBO (Small Intestinal Bacterial Overgrowth): Root Causes, Testing, And Evidence-Based Treatment

Small Intestinal Bacterial Overgrowth (SIBO) is a condition where bacteria that belong in the colon colonize the small intestine, where they ferment food too early and drive bloating, pain, and altered bowel habits.

In this post, we will discuss what SIBO actually is at a mechanistic level, why it keeps coming back, the three gas subtypes, why standard breath testing is imperfect, the root causes beyond antibiotics, and an evidence-based approach to treatment.

---

Basics Of SIBO

SIBO is defined as an excessive number of bacteria in the small intestine that produces gastrointestinal symptoms. R

The small intestine is not sterile, but it normally carries far fewer bacteria than the colon, and those bacteria are mostly different species. R

When colon-type bacteria migrate upstream and set up residence in the small bowel, they meet your food before you have finished digesting and absorbing it.

They ferment carbohydrates in the wrong place, producing gas, drawing water into the lumen, and generating byproducts that damage the brush border and the intestinal lining.

The classic symptoms are bloating within an hour or two of eating, abdominal distension, gas, cramping, and either diarrhea or constipation depending on the dominant organisms.

Because the overgrowth interferes with absorption, longstanding SIBO can also cause deficiencies in fat-soluble vitamins, iron, and B12, along with unintended weight changes. R

The single most important thing to understand is that SIBO is almost always a downstream problem, not a primary infection.

It is a signpost pointing at a failure of one of the mechanisms that is supposed to keep the small intestine clean, which is why antibiotics alone so often produce only temporary relief.

The Three Subtypes: Hydrogen, Methane, And Hydrogen Sulfide

Not all SIBO is the same, and the dominant gas produced by the overgrowth predicts both the symptom pattern and the response to treatment.

Hydrogen-dominant SIBO is driven by fermenting bacteria that release hydrogen gas, and it tends to present with diarrhea, urgency, and bloating.

Methane-dominant overgrowth is now formally called Intestinal Methanogen Overgrowth (IMO), because the organisms responsible are not bacteria at all. R

They are archaea, most often Methanobrevibacter smithii, and they consume hydrogen produced by other microbes and convert it to methane. R

Methane slows intestinal transit, which is why IMO is tightly associated with constipation, and the degree of methane elevation correlates with the severity of constipation. R

Because methanogens can colonize the entire gut and not just the small bowel, IMO is technically a broader term than SIBO.

Hydrogen sulfide SIBO is the most recently characterized subtype, driven by sulfate-reducing organisms such as Desulfovibrio that consume hydrogen and produce hydrogen sulfide gas.

Elevated breath hydrogen sulfide correlates with diarrhea-predominant symptoms and with a higher relative abundance of sulfide-producing bacteria. R

This subtype was invisible to older two-gas breath tests, so a subset of patients who "tested normal" for years actually had a sulfide-driven overgrowth the whole time.

Knowing your subtype matters because methane responds to different antimicrobials than hydrogen, and sulfide overgrowth responds to reducing sulfur load in the diet.

SIBO, IMO, SIFO, And LIBO Are Not The Same Thing

Four overlapping labels get used interchangeably, and they describe different organisms, in different places, confirmed by different tests, with very different amounts of evidence behind them. R

Confusing them is why a lot of people spend a year treating the wrong thing.

The SIBO and IMO thresholds in that table are the current ACG and North American Consensus criteria. R R

The lower aspirate cutoff is the one the culture-plus-sequencing work supports, since duodenal microbial diversity, network structure, and symptom severity all shift at 10³ CFU/mL rather than at 10⁵. R

SIBO is also the only row in that table with a case-control evidence base behind it, at a pooled odds ratio of 3.7 for SIBO in irritable bowel syndrome versus controls across 25 studies, 3,192 patients, and 3,320 controls. R

The IMO frequency figure is the pooled prevalence of methane-positive overgrowth across 17 studies and 1,653 patients with irritable bowel syndrome, which came out at 25.0 percent, and was three times higher in the constipation-predominant subtype than in the diarrhea-predominant one. R

IMO carries the organism in its name rather than a location because Methanobrevibacter smithii is the dominant methanogen in the human gut, and it is enriched in constipation-predominant IBS alongside higher methane output. R

Those archaea colonize the colon as well as the small intestine, which is why the ACG dropped the word small from the label. R

The constipation row is the best supported symptom link in the whole table, with methane on breath testing carrying a pooled odds ratio of 3.51 for constipation across nine studies and 1,277 subjects. R

Two of those rows are worth reading twice.

Small Intestinal Fungal Overgrowth (SIFO) is the entity most often missed, because it produces the same belching, bloating, indigestion, nausea, gas, and diarrhea as bacterial overgrowth, and no breath test will find it. R

It is confirmed only by aspirating small bowel fluid during upper endoscopy and culturing it, which is why it stays invisible in a workup built entirely around breath testing. R

There is still no standardized protocol for that fungal culture, and the aspirate itself has to be collected under aseptic conditions through a catheter passed at enteroscopy. R R

It is also not rare in the population that actually gets tested, since two studies found SIFO in roughly a quarter of patients with unexplained gastrointestinal symptoms, 24 of 94 in one and 38 of 150 in the other. R

Candida is the dominant organism, and the same two risk factors that drive bacterial overgrowth, dysmotility and proton pump inhibitor use, independently drive fungal overgrowth as well. R

Prolonged antibiotic exposure and immunosuppression sit on the SIFO risk list alongside them, which is a different set of levers than the ones that produce bacterial overgrowth. R

Large Intestinal Bacterial Overgrowth (LIBO) is the row that should make you skeptical.

The 2023 review that formally compared all four entities notes that the term has emerged in scientific circles and at conferences, then states that such a claim has yet to be figured out in any medical article. R

There is no threshold, no validated test, and no agreed definition, which is not surprising given that the colon is supposed to carry vastly more bacteria than the small intestine. R R

Overgrowth is a density concept, and in an organ built to be densely colonized, the meaningful question is composition rather than count.

That question is dysbiosis, which is a real and useful idea, but it is an umbrella term rather than a diagnosis with a cutoff. R

A 2024 review in Gut put the problem plainly, describing dysbiosis as a term that broadly links microbial imbalances to various chronic illnesses without precision or definition. R

Why The Distinction Changes Treatment

These four do not respond to the same protocol, and treating all of them as SIBO is how people end up cycling antimicrobials for years. R

Methanogens are archaea rather than bacteria, so they do not respond to rifaximin the way hydrogen producers do, and clearing methane generally requires adding a second agent. R

That is a phylogenetic fact before it is a clinical one, since cultured human methanogens are highly resistant to ampicillin, streptomycin, gentamicin, rifampicin, ofloxacin, and tetracycline, and stay susceptible mainly to the few molecules that also work against eukaryotes. R

The clinical version showed up in a neomycin trial in constipation-predominant IBS, where the improvement was concentrated in the patients who were producing methane. R

Fungi do not respond to antibacterials at all, and a course of antibiotics aimed at presumed SIBO can make fungal overgrowth worse by removing the bacterial competition. R

That competition is a real mechanism rather than a metaphor, since commensal anaerobes maintain colonization resistance against Candida through host antimicrobial peptide signaling, and broad-spectrum antibiotics remove it. R R

Methane-dominant overgrowth pushes toward constipation while hydrogen and hydrogen sulfide push toward diarrhea, so the prokinetic and dietary plan diverges from the moment you know which gas you are dealing with. R R R

Methane is not only a marker of that split, because infusing it into an animal small bowel slows transit and augments contractile activity directly. R

And if the label is LIBO, there is nothing to eradicate, because what is being described is colonic dysbiosis, which is rebuilt rather than killed.

Each entity now has its own deep dive:

Intestinal Methanogen Overgrowth: The archaeal biology, why methane slows transit, and the antimicrobial combinations that work on methanogens when rifaximin alone does not.

Large Intestinal Bacterial Overgrowth: Why the term exists, what evidence does and does not support it, and what people are usually describing when they use it.

Small Intestinal Fungal Overgrowth: The fungal side, the aspirate-only diagnosis, and the overlap with antibiotic exposure and acid suppression.

For the colonic foundation sitting underneath all four, see dysbiosis, and for the systemic side of fungal overgrowth beyond the gut, see candida overgrowth.

All four of these are downstream of the same question of who is allowed to live where, which I take apart in the Bacteria Rule, We're Just Squatting Here chapter.

What Causes SIBO

SIBO is a consequence of a broken defense mechanism, and identifying which one is broken is the entire game.

The most common and most overlooked driver is impaired motility of the small intestine, specifically loss of the cleansing wave called the Migrating Motor Complex (MMC), which is covered in detail in the next section.

Root causes of SIBO (not an exclusive list):

• Adhesions and structural obstruction from prior abdominal surgery, endometriosis, or Crohn's strictures that create pockets of stasis
• Bile insufficiency from gallbladder removal or cholestasis, since bile acids are directly antimicrobial in the small bowel
• Hypochlorhydria (low stomach acid), often from chronic acid-suppressing medication, which removes the acid barrier that sterilizes incoming food R
• Ileocecal valve dysfunction, where the one-way gate between the small intestine and colon fails and allows colonic bacteria to reflux upstream
• Impaired migrating motor complex from post-infectious autoimmunity, diabetes, hypothyroidism, or opioid use
• Pancreatic enzyme insufficiency, which leaves undigested substrate in the lumen for bacteria to ferment R

The post-infectious pathway deserves special attention because it explains a large fraction of cases that seem to come out of nowhere.

After a bout of food poisoning, the immune system produces antibodies against a bacterial toxin called cytolethal distending toxin B (CdtB).

Through molecular mimicry, those antibodies cross-react with vinculin, a protein your own gut nerve cells use, and the resulting autoimmune damage impairs the migrating motor complex. R

This is why so many people trace their SIBO back to a single memorable case of traveler's diarrhea or food poisoning.

Underlying dysbiosis in the colon also raises the baseline pressure of bacteria trying to migrate upstream, which is why gut health upstream and downstream of the small intestine both matter.

How The Small Intestine Keeps Itself Clean

The small intestine has a layered defense system, and SIBO is what happens when enough of those layers fail at once.

The migrating motor complex is the master defense.

It is a wave of coordinated muscular contractions that sweeps through the stomach and small intestine roughly every 90 to 120 minutes during fasting, physically clearing residual food, debris, and bacteria toward the colon. R

It has been called the intestinal housekeeper, and Phase III of the complex is the powerful sweeping contraction that does most of the cleaning.

The critical evidence linking the MMC to SIBO is old but definitive.

Patients with bacterial overgrowth were shown decades ago to have an absent or disordered migrating motor complex, and disrupting the MMC experimentally is enough to produce overgrowth on its own. R

The MMC only runs when you are fasting, and it is suppressed every time you eat, which is why constant snacking is quietly one of the worst habits for someone prone to SIBO. R

Stomach acid is the second layer, sterilizing most of what you swallow before it reaches the small intestine, which is why suppressing acid raises overgrowth risk. R

Bile and pancreatic secretions are the third layer, since bile acids are antimicrobial and enzymes prevent undigested food from feeding bacteria. R

The ileocecal valve is the fourth layer, acting as a one-way gate that keeps the dense colonic population from washing back into the small bowel.

The gut immune system, including secretory IgA and the intestinal lining itself, is the final layer, and once bacterial products like lipopolysaccharide accumulate they can inflame and loosen the barrier further.

When the housekeeper stops sweeping, the acid barrier is down, and the valve leaks, bacteria have every advantage, and SIBO becomes self-sustaining.

SIBO And Overlapping Conditions

SIBO rarely travels alone, and its comorbidities are a clue to shared underlying mechanisms.

Conditions that overlap with SIBO (not an exclusive list):

• Diabetes and hypothyroidism, both of which slow gut motility and impair the migrating motor complex
• Ehlers-Danlos syndrome and hypermobility, where connective tissue laxity contributes to dysmotility, and SIBO prevalence runs high in this group R
• Gastroparesis and chronic constipation, which share the motility deficit at the root of SIBO
• Histamine intolerance and mast cell issues, since overgrowth feeds histamine production and barrier disruption, discussed in histamine intolerance versus MCAS
• Irritable bowel syndrome, where a large fraction of cases show abnormal breath tests and post-infectious autoimmunity R
• Rosacea and skin conditions tied to intestinal permeability and zonulin
• Scleroderma and connective tissue disease, the textbook example of severe dysmotility-driven overgrowth

The thread running through most of these is motility.

Anything that damages the nerves or muscle of the gut, whether autoimmune, metabolic, or structural, tends to allow overgrowth downstream.

This is also why chasing the bacteria without addressing the comorbid driver produces relapse after relapse.

Why Standard Breath Testing Is Imperfect

Breath testing is the most widely used SIBO test, and it is genuinely useful, but you should understand its real limitations before you put too much weight on a single result.

The test works by having you drink a sugar substrate, usually lactulose or glucose, and then measuring hydrogen and methane in your breath at intervals, since those gases come only from bacterial fermentation. R

The problem is accuracy.

A meta-analysis of breath testing found the lactulose breath test had a pooled sensitivity of only 42 percent and specificity of 71 percent, while the glucose breath test reached 55 percent sensitivity and 83 percent specificity. R

In plain terms, a normal breath test does not rule SIBO out, and the two substrates disagree with each other often enough to matter.

Glucose is absorbed quickly in the upper small intestine, so it can miss overgrowth further downstream, producing false negatives.

Lactulose travels the whole length of the small bowel, but because it eventually reaches the colon, a fast transit time can produce a false positive when the gas rise is really just the substrate hitting the colon early.

There is a big MAYBE built into every breath test, and this is why interpretation should always be anchored to symptoms and pretest probability, not the number alone.

The older tests also measured only hydrogen and methane, missing the hydrogen sulfide subtype entirely, though newer three-gas devices have closed that gap. R

The gold standard, a direct culture of small bowel fluid, has its own problems, since only a minority of gut bacteria grow in culture and the sample is easily contaminated on the way out.

The honest position is that no SIBO test is definitive, so treat the test as one input alongside history, subtype, and response to treatment.

Where The Diagnostic Numbers Came From

The thresholds themselves have a shakier history than most people realize.

The classic ≥ 10⁵ CFU/mL cutoff did not come from a study of people with bloating.

It descends from the blind loop literature, where surgically created stagnant segments of bowel produced counts that high, and a systematic review of 71 papers spanning four decades found no evidence the number was ever formally validated as a diagnostic threshold. R

That older work was investigating fat malabsorption in surgically stagnant loops, which is a structural complication and a different clinical problem from the bloating the cutoff is now used to explain. R

That review's conclusion was blunt, stating that there is no validated diagnostic test or gold standard for SIBO, and that not even the culture papers met basic quality standards. R

The contemporary criterion has moved down accordingly, and the ACG now treats a colony count of ≥ 10³ CFU/mL in a duodenal or jejunal aspirate as a positive result. R

That lower number has since been tested against sequencing rather than assumed, and 10³ CFU/mL is where duodenal diversity collapses, Escherichia and Klebsiella take over, and symptom severity rises. R

That is a hundredfold shift in what counts as abnormal, which is not a rounding adjustment.

It means a large group of people were told for years that their cultures were clean, under a cutoff borrowed from a surgical complication they did not have.

Aspirate has problems beyond the number as well.

The ACG notes there is no standardized technique for collecting the culture, and the catheter passes through the mouth, esophagus, and stomach before it samples anything, so oral flora ride along. R

That matters because the jejunum has its own resident microbiota that is genuinely distinct from the one in the mouth, so oral carryover is not a harmless addition to the count. R

It is also not a rare event, since in one series comparing breath testing to duodenal aspiration directly, roughly one in five aspirates came back flagged as contaminated rather than usable. R

The sample is also a single point in an organ roughly six meters long, so a proximal aspirate can miss a distal overgrowth completely (the same anatomical blind spot that limits glucose breath testing). R

When duodenal and jejunal aspirates were taken from the same patients in the same procedure, duodenal aspirate reached only 74 percent sensitivity against the jejunal result, and among the patients positive at either site the two sites agreed just 58 percent of the time. R

The breath test cutoffs are in the same position, agreed on by expert consensus rather than established against an independent standard, with a hydrogen rise of ≥ 20 ppm above baseline within 90 minutes and a methane level of ≥ 10 ppm at any point taken as positive. R R

Consensus cutoffs exist because clinicians need a number to act on, not because a validation study proved those particular numbers separate sick from well. R

Transit speed is what turns those cutoffs into errors in both directions, because a fast small bowel hands the substrate to the colon before the test window closes and colonic bacteria produce the rise the test credits to the small intestine. R

Running glucose breath tests alongside scintigraphy in 139 patients showed that 48 percent of the positive results were false on exactly that mechanism. R

The mean oro-cecal transit time in the false positive group was 18 minutes, against 79 minutes in the patients who genuinely had overgrowth and 86 minutes in the ones who tested negative. R

The same study found that colonic fermentation accounted for 65 percent of positives in patients with prior upper gastrointestinal surgery and 13 percent in patients without it, so an identical cutoff carries a different meaning depending on how the bowel was plumbed. R

Pairing the breath test with a scintigraphic transit measurement is the standing proposal for separating the two signals, and it reproduces almost perfectly, but it is not what a routine breath test does. R

Methane runs the error the other way, because methane producers have measurably slower small bowel and colonic transit than hydrogen producers, so the substrate can still be upstream of the colon when the clock runs out. R

None of this means testing is useless, and it does mean the result is evidence rather than a verdict.

How To Improve SIBO

The evidence-based approach to SIBO has three parts that must all happen or the overgrowth returns: reduce the bacterial load, remove the fuel temporarily, and restore the defense that failed.

Skipping the third step is the single most common reason SIBO relapses within months.

1. Reduce The Bacterial Load

Rifaximin is the best-studied antibiotic for hydrogen-dominant SIBO, and it is a reasonable first-line choice because it stays almost entirely in the gut with minimal systemic absorption.

A meta-analysis found an overall eradication rate around 70 percent by breath test, with a low adverse event rate, though the underlying studies are of modest quality. R

Methane-dominant overgrowth responds better to rifaximin combined with a second agent that targets archaea, since methanogens resist rifaximin alone. R R

Rifaximin is a prescription, so this is a conversation to have with a physician, and you can reach out through the consultation page if you want help building a plan.

Herbal antimicrobials are a legitimate alternative for people who cannot or prefer not to use antibiotics.

A study at Johns Hopkins found herbal antimicrobial protocols achieved breath test normalization at rates statistically equivalent to rifaximin. R

The herbal agents with the most support are combined into standard protocols, alphabetically:

Allicin: Stabilized garlic extract, valued particularly for methane-dominant overgrowth.

Berberine: A plant alkaloid with broad antimicrobial activity that is one of the two best-supported botanicals for SIBO, available as a berberine supplement.

Neem: A traditional antimicrobial with preclinical support, often rotated with other botanicals.

Oregano oil: A potent antimicrobial, the other most-studied botanical alongside berberine.

Biofilms can shelter bacteria from both antibiotics and herbs, which is one reason overgrowth is stubborn, and disrupting them is covered in the post on inhibiting biofilms.

What The Antibiotic Numbers Actually Say

The ACG guideline tabulates eradication rates for the antibiotics used in SIBO, and the spread across agents is worth looking at carefully. R

Reported eradication rates by agent (not a head-to-head comparison):

• Ciprofloxacin 500 mg twice daily, 43 to 100 percent R
• Metronidazole 250 mg three times daily, 43 to 87 percent R
• Rifaximin 550 mg three times daily, 61 to 78 percent R
• Tetracycline 250 mg four times daily, 87.5 percent R
• Trimethoprim-sulfamethoxazole 160/800 mg twice daily, 95 percent R

Read at face value, that table says trimethoprim-sulfamethoxazole beats rifaximin by more than twenty points, and that reading is wrong.

A range of 43 to 100 percent for a single drug is not a measurement of that drug.

It is a measurement of how much the underlying studies disagree with each other.

Those figures come from separate small trials that used different substrates, different cutoffs, different treatment durations, and different definitions of what counts as eradication, and almost none of them compared one agent against another in the same patients. R R

Rifaximin is the one agent with enough studies behind it to measure that disagreement, and pooling 32 studies and 1,331 patients gives an eradication rate of 70.8 percent with an I² of 89.4 percent, which is near the top of the scale that statistic can register. R

The same analysis found that drug dose, study design, and whether a co-therapy was given each independently moved the eradication rate, and its authors concluded that the quality of the available studies is generally poor. R

Part of the spread is that the tests used to declare eradication do not agree with each other either, since lactulose breath testing and duodenal aspiration matched in only 63.5 percent of patients tested both ways, at a kappa of essentially zero. R

The single-number entries are the least trustworthy of all, because 87.5 percent and 95 percent are the kind of false precision you get from a handful of patients in one small study, not from a body of evidence.

When the trials are pooled properly the picture flattens out considerably, with antibiotics normalizing the breath test in 51.1 percent of patients versus 9.8 percent on placebo, and the authors specifically flagged modest study quality, small sample sizes, and heterogeneous design. R

That is the number to hold in your head.

Antibiotics beat placebo clearly, and the apparent superiority of any one agent over another is mostly noise. R

Rifaximin remains a reasonable first choice not because its number is the highest but because it stays in the gut, and methane-dominant overgrowth still needs a second agent regardless of what the table implies. R R

It is a rifamycin engineered for low gastrointestinal absorption, so intraluminal and fecal concentrations run far above the minimum inhibitory concentrations while systemic exposure stays negligible. R

Recurrence Is The Real Outcome

Eradication is the easy part, and it is also the wrong endpoint to judge a treatment on.

Eighty patients who successfully cleared SIBO with rifaximin were followed with repeat glucose breath tests, and positivity returned in 12.6 percent at three months, 27.5 percent at six months, and 43.7 percent at nine months. R

Symptoms tracked the tests, rising significantly at every timepoint in the patients whose breath tests turned positive again. R

Older age, prior appendectomy, and chronic proton pump inhibitor use all predicted recurrence, which is a list of mechanical and chemical defense failures rather than a list of bacterial traits. R

The acid suppression signal has since been confirmed at scale, with 29 studies and 3,682 treated patients giving an odds ratio of 2.14 for SIBO, and each additional month of therapy adding to the risk. R

A curve that climbs steadily to nearly half the cohort within nine months is not the shape you see when a treatment cures an infection.

It is the shape you see when a treatment removes an accumulation that the underlying system keeps regenerating.

If SIBO were a primary infection, eradication would be durable and that curve would flatten out after the first few months.

The clearance mechanism in question was described in 1977, when the patients whose interdigestive motor complex was absent or badly disordered turned out to be the ones with demonstrable bacterial overgrowth. R

Because it is a downstream consequence of a clearance mechanism that failed, the overgrowth simply reaccumulates on roughly the same timescale it took to build the first time.

This is the strongest single argument that SIBO is a signpost rather than a disease, and it is why step 3 below matters more than step 1 does.

My hypothesis is that this reaccumulation pattern is what a stalled Wound Healing Cycle (WHC) looks like from the gut end, where the system keeps regenerating the same problem because the repair sequence never completes, which I cover in the Moving from Chronic Inflammation to Wound Healing chapter.

The practical read is that the antimicrobial buys you a window, and what you do inside that window decides whether you are back here in nine months.

2. Remove The Fuel

Fermentable carbohydrates are what the overgrowth eats, so restricting them starves the bacteria and calms symptoms while you treat.

A low FODMAP diet ranks first among dietary strategies for improving global IBS symptoms, abdominal pain, and bloating in network meta-analysis, and it overlaps heavily with SIBO management. R

Low FODMAP is a temporary therapeutic tool, not a permanent diet, because long-term restriction starves your beneficial Bifidobacteria and reduces microbial diversity.

For the hydrogen sulfide subtype, additionally lowering high-sulfur foods often produces faster relief than FODMAP restriction alone.

The most aggressive option is an elemental diet, a predigested formula absorbed high in the small intestine that leaves almost nothing for bacteria downstream.

A 14-day elemental diet normalized the lactulose breath test in roughly 80 percent of subjects, with a further 5 percent normalizing by day 21. R

Elemental formulas are demanding to tolerate, so most people use them as a two-week reset rather than a lifestyle, and a ready-made elemental diet formula makes it more practical.

3. Restore The Defense That Failed

This is the step that determines whether you stay well.

If motility is the driver, a prokinetic taken at night supports the migrating motor complex during the fasting window and is the mainstay of relapse prevention.

Prescription prokinetics like low-dose prucalopride or erythromycin are the strongest options, and natural agents include ginger and melatonin, which supports gut motility beyond its role in sleep. R

Space your meals four to five hours apart and stop snacking, because every bite shuts the housekeeper off and constant grazing is a self-inflicted cause of relapse.

If low stomach acid is the driver, betaine HCl with meals can restore the acid barrier, though it should be avoided if you have active gastritis or ulcers.

If bile or enzyme insufficiency is the driver, digestive enzymes and bile support such as TUDCA address the missing antimicrobial secretions.

Once the overgrowth is cleared and the defense is restored, the rebuilding phase reintroduces fermentable fiber and beneficial organisms to restore diversity.

This is where resistant starch, short chain fatty acids like butyrate, and targeted Lactobacillus and Bifidobacteria strains come back in, slowly.

For severe, refractory dysbiosis underneath the overgrowth, fecal microbiota transplantation is an emerging option, though it is not a first-line SIBO treatment. R

What To Stay Away From

Some common habits and interventions actively feed SIBO or blunt the defenses you are trying to rebuild.

Things to avoid or minimize with SIBO (not an exclusive list):

• Constant snacking and grazing, which suppresses the migrating motor complex all day
• High-dose probiotics during active overgrowth, which can worsen bloating in some people until the load is reduced (reintroduce them in the rebuilding phase)
• Long-term acid-suppressing drugs where not strictly necessary, given the link between acid suppression and overgrowth, discussed in proton pump inhibitors and the gut R R
• Opioids and unnecessary anticholinergics, which slow gut motility directly
• Permanent ultra-restrictive dieting, which starves beneficial bacteria and reduces diversity
• Sugar alcohols and excess fermentable fiber during the active phase, which are direct fuel for the overgrowth

The overarching principle is to avoid anything that either feeds the bacteria or turns off the housekeeper.

Testing

Testing for SIBO has two goals: confirm the overgrowth and its subtype, and find the root cause driving it.

Breath Testing And Subtyping

The three-gas breath test is the most complete option because it captures the hydrogen sulfide subtype that older tests miss.

I use the trio-smart SIBO Breath Test (Gemelli Biotech) to measure hydrogen, methane, and hydrogen sulfide together, which is the only way to identify all three subtypes in one test. R

For a classic two-gas lactulose approach, the SIBO Test (3-Hour) or the shorter SIBO Test (2-Hour) (Genova Diagnostics) measure hydrogen and methane across the small bowel transit.

Interpret every breath test against symptoms and pretest probability, because sensitivity is modest and a normal result does not rule SIBO out. R

Root Cause And Post-Infectious Markers

To identify the post-infectious autoimmune driver, I use the ibs-smart (Gemelli Biotech) blood test, which measures anti-CdtB and anti-vinculin antibodies. R

Positive antibodies point to migrating motor complex damage from a prior gut infection, which changes the plan toward long-term prokinetic support.

Comprehensive Gut And Barrier Panels

To assess the colonic dysbiosis, pathogens, and barrier integrity underneath the overgrowth, I use the Gut Zoomer (Vibrant Wellness), which profiles the microbiome, permeability markers like zonulin, and digestion.

For a PCR-based stool alternative, the GI-MAP (Diagnostic Solutions) quantifies pathogens, commensals, and methanogens including Methanobrevibacter smithii.

To directly measure the leaky barrier that often accompanies SIBO, the Intestinal Permeability Assessment (Genova Diagnostics) uses the lactulose to mannitol ratio.

Mechanisms Of Action

Simple:

• SIBO happens when the wave that sweeps your small intestine clean between meals slows down and lets colon bacteria move in and stay.
• Those bacteria ferment your food too early, producing gas that causes bloating, and byproducts that inflame the gut lining.
• Methane gas from archaea slows the gut and causes constipation, while hydrogen and hydrogen sulfide gases speed it up and cause diarrhea.

Advanced:

• Migrating motor complex failure. The MMC is a cyclical interdigestive motor pattern regulated by motilin and the enteric nervous system, and its Phase III sweeping contractions clear luminal contents toward the colon roughly every 90 to 120 minutes during fasting. R Loss of the MMC, whether from autoimmune neuropathy, diabetic vagal damage, or opioid receptor activation, removes the primary mechanical clearance of the small bowel and permits colonization. R
• Molecular mimicry and anti-vinculin autoimmunity. After enteric infection with organisms expressing cytolethal distending toxin, anti-CdtB antibodies cross-react with vinculin, a cytoskeletal adhesion protein expressed by interstitial cells of Cajal, the pacemaker cells that generate the MMC. R The resulting loss of interstitial cell of Cajal function degrades motility and sustains overgrowth.
• Interspecies hydrogen transfer. Fermenting bacteria produce hydrogen, and methanogenic archaea such as Methanobrevibacter smithii and sulfate-reducing bacteria such as Desulfovibrio consume that hydrogen, producing methane and hydrogen sulfide respectively. R Methane acts as a neuromuscular slowing signal that prolongs transit and drives constipation, while hydrogen sulfide is cytotoxic to colonocytes and associates with diarrhea. R R
• Loss of chemical barriers. Gastric acid, bile acids, and pancreatic enzymes together sterilize and clear incoming contents, so hypochlorhydria from acid suppression measurably raises overgrowth risk by removing the proximal chemical barrier. R

Genetics

SIBO is not a monogenic disease, but host genetics shape susceptibility through motility, connective tissue, and immune targets.

VCL

VCL encodes vinculin, a cytoskeletal protein that anchors cell-to-cell and cell-to-matrix junctions, including in the interstitial cells of Cajal that pace the migrating motor complex.

In post-infectious SIBO, autoantibodies raised against bacterial CdtB cross-react with vinculin, and higher anti-vinculin levels track with more severe symptoms. R

This is an acquired autoimmune hit on a structural gene product rather than an inherited VCL mutation, but it explains the durable motility damage after food poisoning.

COL genes (connective tissue)

Collagen genes underlie the heritable connective tissue disorders, and defects in them produce joint hypermobility and Ehlers-Danlos syndrome.

Connective tissue laxity contributes to gastrointestinal dysmotility, and SIBO prevalence is elevated in hypermobile and Ehlers-Danlos populations. R

This is why unexplained recurrent SIBO in a flexible, easily bruised patient should prompt a look at the connective tissue picture.

More Research

Antibiotic resistance and rifaximin deserves ongoing attention, because although rifaximin has a favorable resistance profile compared with systemic antibiotics, repeated courses without addressing the root cause are still not a durable strategy. R

Breath test standardization remains unsettled, since substrate choice, cutoffs, and transit time all shift results, and clinicians still disagree on the best protocol, which is why interpretation matters as much as the raw number. R

Elemental diet as a non-antibiotic reset is a striking finding that remains underused, given how effective a two-week formula was at normalizing the breath test, and it is worth considering for antibiotic-intolerant patients. R

Herbal versus antibiotic equivalence rests largely on a single retrospective study, so while promising, it should not yet be read as settled science, and better randomized trials are underway. R

Hydrogen sulfide as a distinct subtype is a genuinely new axis of understanding, and three-gas testing is reclassifying patients who were told for years that their tests were normal. R

For biomarker and subtype testing I use the trio-smart SIBO Breath Test and the ibs-smart to separate the mechanical from the autoimmune drivers, and you can track your labs, symptoms, and treatment response over time in the Health Hub with a Pro membership.

If you want a deeper look at how the gut barrier and bacterial byproducts drive systemic symptoms, the post on MCT oil types and the piece on Akkermansia muciniphila cover the rebuilding side, and dysbiosis covers the colonic foundation underneath it all.